iNNCOVACC: India's First Intranasal COVID-19 Vaccine Launched

iNNCOVACC, the world's first intranasal COVID-19 vaccine has been unveiled by Union Health Minister Mansukh Mandaviya.

iNNCOVACC vaccine had received approval for the primary 2-dose schedule, and as a heterologous booster dose. It is developed by Bharat Biotech International Limited (BBIL) in collaboration with Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the Department of Biotechnology, Ministry of Science and Technology.

COVID-19 Vaccine: Myths and Facts
Debunking several misconceptions or myths that have surfaced regarding covid vaccination is important and focus on the facts related to COVID-19 vaccines.

‘iNCOVACC, the intranasal COVID-19 vaccine is a cost efficient COVID-19 vaccine, saving costs linked to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for injectable vaccines.’

Tweet it Now

Expressing his elation at the event, Mandaviya said that over 65 per cent of vaccines supplied in the world are from India.

Congratulating the BBIL team and the Department of Biotech for bringing about the world's first nasal vaccine, he stated that "being the world's first intra-nasal COVID-19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat."

The Union Health Minister added that India's vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines.

COVID Vaccination for Pregnant Women
The Indian Government has approved Covid-19 vaccination of pregnant women, who are to be counselled and informed regarding the risks and benefits of the vaccines.

Congratulating BBIL for innovating another vaccine in collaboration with BIRAC, Jitendra Singh said that "India has taken a lead in developing vaccines and medicines for diseases common in the developing world."

India's First COVID-19 Intranasal Vaccine iNCOVACC

He also stated that ZyCoV-D, the world's first and India's indigenously developed DNA based vaccine for COVID-19 to be administered in humans including children and adults 12 years and above, was also developed in partnership with the Department of Biotechnology in the Ministry of Science & Technology under 'Mission Covid Suraksha' through BIRAC.

It utilizes a vector-based platform, which can be easily updated with emerging variants leading to large scale production, within a few months. These rapid response timelines combined with the ability of cost effective and easy intranasal delivery, makes it an ideal vaccine to address future infectious diseases.

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

A rollout of iNCOVACC is expected to begin in private hospitals that have placed advance orders. Initial manufacturing capacity of several million doses per annum has been established, this can be scaled up to a billion doses as required. iNCOVACC is priced at Rs 325 per dose for large volume procurement by State Governments and Government of India.

Source-IANS

Second Dose of COVID-19 Vaccine Linked to Heart Inflammation in Males
The incidence of mRNA vaccine-associated myopericarditis was higher in boys between 12 and 20 years after the second dose of the COVID-19 vaccine.